IL-23–Mediated Psoriasis-Like Epidermal Hyperplasia Is Dependent on IL-17A

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Immunology

• Publication date

  2011-02-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.4049/jimmunol.1001001PMID 21172868
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vivo measurement of epidermal thickness changes associated with tumor promotion in murine models.

  2010cited by this paper
• Circulating Th17, Th22, and Th1 cells are increased in psoriasis.

  2010cited by this paper
• Increased IL-23 expression in palmoplantar psoriasis and hyperkeratotic hand dermatitis.

  2010cited by this paper
• Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.

  2010cited by this paper
• Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

  2010cited by this paper
• Characterization of the interleukin‐17 isoforms and receptors in lesional psoriatic skin

  2009cited by this paper
• IL-17 and Th17 Cells.

  2009cited by this paper
• CCR6 is required for IL-23-induced psoriasis-like inflammation in mice.

  2009influential reference
• Properties and origin of human Th17 cells.

  2009cited by this paper
• Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis

  2009cited by this paper
• Interleukin-17 and type 17 helper T cells.

  2009cited by this paper
• The IL-23/Th17 axis in the immunopathogenesis of psoriasis.

  2009cited by this paper
• Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis: Results of a Randomized, Placebo-Controlled, Phase 2 Trial

  2009cited by this paper
• Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis.

  2009cited by this paper
• Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.

  2008cited by this paper
• Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

  2008cited by this paper
• Th17 cytokines interleukin (IL)‐17 and IL‐22 modulate distinct inflammatory and keratinocyte‐response pathways

  2008cited by this paper
• Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).

  2008cited by this paper
• Genomewide Scan Reveals Association of Psoriasis with IL-23 and NF-κB Pathways

  2008cited by this paper
• Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells.

  2008cited by this paper
• A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes.

  2007cited by this paper
• Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis

  2007influential reference
• Development, cytokine profile and function of human interleukin 17–producing helper T cells

  2007cited by this paper
• Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses

  2007cited by this paper
• A role for T cell‐derived interleukin 22 in psoriatic skin inflammation

  2007cited by this paper
• Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis

  2007cited by this paper
• The Effects of IL-20 Subfamily Cytokines on Reconstituted Human Epidermis Suggest Potential Roles in Cutaneous Innate Defense and Pathogenic Adaptive Immunity in Psoriasis

  2007cited by this paper
• IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesis

  2006influential reference
• In Vitro and In Situ Expression of IL-23 by Keratinocytes in Healthy Skin and Psoriasis Lesions: Enhanced Expression in Psoriatic Skin

  2006cited by this paper
• Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides

  2006cited by this paper
• IL‐22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis

  2006cited by this paper
• Characterization of age-related effects in human skin: A comparative study that applies confocal laser scanning microscopy and optical coherence tomography.

  2004cited by this paper
• Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris

  2004cited by this paper
• IL-23 Production by Cosecretion of Endogenous p19 and Transgenic p40 in Keratin 14/p40 Transgenic Mice: Evidence for Enhanced Cutaneous Immunity

  2003cited by this paper
• Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses.

  2002influential reference
• Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes.

  2000cited by this paper
• Epidermal turnover time.

  1994cited by this paper

• Elephantopus scaber suppresses ConA-induced T cell activation by inhibiting NF-κB and Ca2+/NFAT signaling.

  2026cites this paper
• Small molecule interleukin (IL) 17A/A antagonists and antibodies blocking both IL17A/A and IL17A/F demonstrate equivalent degrees of efficacy in preclinical models of skin and joint inflammation.

  2025cites this paper
• Salivary Interleukins as Non-Invasive Biomarkers for Psoriasis: Advances and Challenges in Diagnosis and Monitoring

  2025cites this paper
• Pharmacological Inhibition of RORγ Ameliorates Skin Inflammation Induced by Both Antigen- and Cytokine-Activated Th17 Cells.

  2025cites this paper
• Development and function of γδ T cells.

  2025cites this paper
• TNFSF14‐HVEM/LTβR Exacerbates Keratinocyte Abnormalities and IMQ‐Induced Psoriatic Skin Inflammation via Activating NF‐κB/TWIST1 Signalling Pathway

  2025cites this paper
• Study of the Therapeutic Effect of Cytokine-Preconditioned Mesenchymal Stem Cells and Their Exosomes in a Mouse Model of Psoriasis

  2025cites this paper
• Celastrol directly targets LRP1 to inhibit fibroblast-macrophage crosstalk and ameliorates psoriasis progression

  2025cites this paper
• A Novel HDAC6 Inhibitor Ameliorates Imiquimod-Induced Psoriasis-Like Inflammation in Mice

  2025cites this paper
• The Therapeutic Potential of Extracellular Vesicles in Psoriasis Treatment: Mechanisms, Applications, and Prospects

  2025cites this paper
• Exploring the pathogenesis and immunological profiles of psoriasis complicated with MASLD

  2024cites this paper
• Cytokines in psoriasis: From pathogenesis to targeted therapy.

  2024cites this paper
• Mouse Models of Itch.

  2024cites this paper
• Review: A Contemporary, Multifaced Insight into Psoriasis Pathogenesis

  2024cites this paper
• Roles of tumor necrosis factor-like ligand 1A in γδT-cell activation and psoriasis pathogenesis

  2024influential citation
• Topical Application of Dipyridamole and Roflumilast Combination Nanoparticles Loaded Nanoemulgel for the Treatment of Psoriasis in Rats

  2024cites this paper
• Effects of Different Therapeutic Approaches on Redox Balance in Psoriatic Patients

  2024cites this paper
• GRP78 Downregulation in Keratinocytes Promotes Skin Inflammation Via the Recruitment and Activation of CCR6+ IL-17A-producing γδ T Cells.

  2024cites this paper
• Inflammatory Cytokines in Psoriatic Arthritis: Understanding Pathogenesis and Implications for Treatment

  2023cites this paper
• Epicutaneous Sensitization to the Phytocannabinoid β-Caryophyllene Induces Pruritic Inflammation

  2023cites this paper
• Preclinical study models of psoriasis: State-of-the-art techniques for testing pharmaceutical products in animal and nonanimal models.

  2023cites this paper
• IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases

  2023cites this paper
• Paradoxical Reactions to Anti-TNFα and Anti-IL-17 Treatment in Psoriasis Patients: Are Skin and/or Gut Microbiota Involved?

  2023cites this paper
• The biological basis of disease recurrence in psoriasis.

  2023cites this paper
• Proteomic and Metabolomic Changes in Psoriasis Preclinical and Clinical Aspects

  2023cites this paper
• Role of γδ T Lymphocytes in the Pathogenesis of Autoimmune Diseases with Skin Lesions

  2023cites this paper
• IL-17A expression by both T cells and non-T cells contribute to HSV-IL-2-induced CNS demyelination

  2023cites this paper
• Psoriasis between Autoimmunity and Oxidative Stress: Changes Induced by Different Therapeutic Approaches

  2022cites this paper
• The Role of Interleukins in the Pathogenesis of Dermatological Immune-Mediated Diseases

  2022cites this paper
• Current understanding of the role of tyrosine kinase 2 signaling in immune responses

  2022cites this paper
• Association Between Psoriasis and Nonalcoholic Fatty Liver Disease Among Outpatient US Adults.

  2022cites this paper
• Effect of Tadalafil in Comparison with Clobetasol ointment in induced Psoriasis in Mice Male

  2022cites this paper
• BJD_20963 773..781

  2022cites this paper
• Istradefylline, an adenosine A2a receptor antagonist, inhibits the CD4+ T-cell hypersecretion of IL-17A and IL-8 in humans

  2022cites this paper
• γδ T Cells in Skin Inflammation.

  2022cites this paper
• Impact of Chronic Inflammation in Psoriasis on Bone Metabolism

  2022cites this paper
• Assessment of skin toxicity in an in vitro reconstituted human epidermis model using deep learning.

  2022cites this paper
• Review and Practical Guidance on Managing Fungal Infections in Patients With Psoriasis Receiving Anti-IL-17 Therapies

  2022cites this paper
• Aloperine Ameliorates IMQ-Induced Psoriasis by Attenuating Th17 Differentiation and Facilitating Their Conversion to Treg

  2022cites this paper
• The Role of T Helper 22 Cells in Dermatological Disorders

  2022cites this paper
• Could Targeted Pharmacotherapies Exert a “Disease Modification Effect” in Patients with Chronic Plaque Psoriasis?

  2022cites this paper
• Drug safety evaluation of ixekizumab for psoriasis: a review of the current knowledge

  2022cites this paper
• Update on the etiopathogenesis of psoriasis (Review)

  2022cites this paper
• Chinese herbal medicine Jia Wei Jing Xie Yin (JWJXY) ameliorates psoriasis via suppressing the Th17 cell response

  2021cites this paper
• Suppression of IL-23-mediated psoriasis-like inflammation by regulatory B cells

  2021cites this paper
• Allosteric inhibition of SHP2 uncovers aberrant TLR7 trafficking in aggravating psoriasis

  2021cites this paper
• Electrophilic nitro-fatty acids suppress psoriasiform dermatitis: STAT3 inhibition as a contributory mechanism

  2021cites this paper
• Discovery of a novel RORγ antagonist with skin-restricted exposure for topical treatment of mild to moderate psoriasis

  2021cites this paper
• JNK1 Signaling Downstream of the EGFR Pathway Contributes to Aldara®-Induced Skin Inflammation

  2021cites this paper
• Istradefylline, an adenosine A2a receptor antagonist, ameliorates neutrophilic airway inflammation and psoriasis in mice

  2021cites this paper
• Gamma Delta T Cells and Their Pathogenic Role in Psoriasis

  2021cites this paper
• First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of LANCL2 pathway in psoriasis

  2021cites this paper
• Interleukin-17 family members in health and disease

  2021cites this paper
• Exploring the Diverse Immune and Genetic Landscape of Psoriatic Arthritis

  2021cites this paper
• Establishment of an Intradermal Ear Injection Model of IL-17A and IL-36γ as a Tool to Investigate the Psoriatic Cytokine Network

  2021cites this paper
• Dendritic Cells and CCR7 Expression: An Important Factor for Autoimmune Diseases, Chronic Inflammation, and Cancer

  2021cites this paper
• Repurposing the anthelmintic praziquantel to treat psoriasis

  2021cites this paper
• Immune responses and therapeutic options in psoriasis

  2021cites this paper
• Effect of Topical Tadalafil Gel in Imiquimod-induced Psoriasiform Skin Inflammation in Mice

  2021cites this paper
• Nrf2 through Aryl Hydrocarbon Receptor Regulates IL-22 Response in CD4+ T Cells

  2021cites this paper
• Optical control of adenosine A3 receptor function in psoriasis.

  2021cites this paper
• The biological basis of disease recurrence in psoriasis: a historical perspective and current models

  2021cites this paper
• Thrombosis in Psoriasis: Cutaneous Cytokine Production as a Potential Driving Force of Haemostatic Dysregulation and Subsequent Cardiovascular Risk

  2021cites this paper
• A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab

  2021cites this paper
• Complement component 3 prevents imiquimod-induced psoriatic skin inflammation by inhibiting apoptosis in mice.

  2020cites this paper
• C5a/C5aR1 mediates IMQ‐induced psoriasiform skin inflammation by promoting IL‐17A production from γδ‐T cells

  2020cites this paper
• Galectin-8 is upregulated in keratinocyte by IL-17A and promotes proliferation by regulating mitosis in psoriasis.

  2020cites this paper
• Probiotics with ameliorating effects on the severity of skin inflammation in psoriasis: Evidence from experimental and clinical studies

  2020cites this paper
• Keratinocyte transglutaminase 2 promotes CCR6+ γδT-cell recruitment by upregulating CCL20 in psoriatic inflammation

  2020cites this paper
• Discovery of BMS-986251: A Clinically Viable, Potent, and Selective RORγt Inverse Agonist.

  2020cites this paper
• Role of TH17 Responses in Increasing Herpetic Keratitis in the Eyes of Mice Infected with HSV-1

  2020cites this paper
• Tricyclic Sulfones as Potent, Selective and Efficacious RORγt Inverse Agonists - Exploring C6 and C8 SAR Using Late-Stage Functionalization.

  2020cites this paper
• Guselkumab in the treatment of moderate-to-severe plaque psoriasis.

  2020cites this paper
• The development of colitis in Il10−/− mice is dependent on IL-22

  2020cites this paper
• The role of the interleukin‐23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis

  2020cites this paper
• Bimekizumab

  2020cites this paper
• Galectin-7 downregulation in lesional keratinocytes contributes to enhanced IL-17A signaling and skin pathology in psoriasis.

  2020cites this paper
• Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review

  2020cites this paper
• Successful use of the interleukin-17A inhibitor (ixekizumab) in the treatment of psoriatic arthritis

  2020cites this paper
• A measurement of epidermal thickness of fingertip skin from OCT images using convolutional neural network

  2020cites this paper
• Interleukin‐23 pathway at the enthesis: The emerging story of enthesitis in spondyloarthropathy

  2020cites this paper
• Koebner Phenomenon in Classic Juvenile Onset Pityriasis Rubra Pilaris

  2019cites this paper
• Adenoviral gene transfer of a single‐chain IL‐23 induces psoriatic arthritis–like symptoms in NOD mice

  2019cites this paper
• Ets1 suppresses atopic dermatitis by suppressing pathogenic T cell responses.

  2019cites this paper
• Current and emerging biologic and small molecule therapies for atopic dermatitis

  2019influential citation
• T cell–intrinsic prostaglandin E2-EP2/EP4 signaling is critical in pathogenic TH17 cell–driven inflammation

  2019cites this paper
• The influence of ustekinumab on expression of STAT1, STAT3, STAT4, SOCS2, and IL17 in patients with psoriasis and in a control

  2019cites this paper
• IL‐23‐ and Imiquimod‐Induced Models of Experimental Psoriasis in Mice

  2019cites this paper
• Structure-based Discovery of Phenyl (3-Phenylpyrrolidin-3-yl)sulfones as Selective, Orally Active RORγt Inverse Agonists.

  2019cites this paper
• Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight.

  2019cites this paper
• IL‐17C amplifies epithelial inflammation in human psoriasis and atopic eczema

  2019cites this paper
• Interleukin-17 cytokines: Effectors and targets in psoriasis—A breakthrough in understanding and treatment

  2019cites this paper
• Role of bulge epidermal stem cells and TSLP signaling in psoriasis

  2019cites this paper
• cell–driven inflammation

  2019cites this paper
• Janus kinase MAPK : Mitogen activated protein kinase NF-κB : Nuclear factor kappa B PAMPs : Pathogen associated molecular patterns TNF : Tumour-necrosis-factor

  2019cites this paper
• The Role of Purinergic Signalling in Inflammatory Disorders

  2019cites this paper
• Targeting LAT1-mediated amino acid transport in innate and adaptive T cells efficiently controls skin inflammation.

  2019cites this paper
• Targeting L-type amino acid transporter 1 in innate and adaptive T cells efficiently controls skin inflammation

  2019cites this paper
• Defining Early Life Stress as a Precursor for Autoimmune Disease.

  2019cites this paper
• Psoriasis: Obesity and Fatty Acids

  2019cites this paper